News

VTC Seed Fund Adds SWARM Engineering to Portfolio

SWARM Engineering, Inc, the next generation of cognitive software for the food supply chain, announced it has closed funding for a $2.7 million seed round.

SWARM Engineering is a Software-as-a-Service (SaaS) platform specifically for the food supply chain, rapidly solving complex problems such as supply & demand forecasting, optimizing inbound and outbound logistics, or maximizing yield in controlled environment agriculture. SWARM is a ‘no-code’ solution, so end users do not need data science expertise, knowledge of machine learning, or a degree in math to use the software. Business users simply define their problem, and SWARM matches their definition with a curated library of algorithms (which can be added to by customers or 3rd parties) to rapidly deliver a solution via the cloud.

S2G Ventures, a Chicago-based investment firm focused on food and agriculture, led the seed round, which included participation from Serra Ventures via their new AgTech fund, Harvard Business School Alumni, Wells Street Capital, VTC Seed Fund, and Rinvest. Angel investor and former CEO of Bunge, Soren Schroder, also participated in the round. The capital will support continued technological innovation and team growth, to support an expanding list of customers, ranging from growers through to dedicated logistics firms.

SWARM are anticipating continued growth in ag-data, combined with an ongoing scarcity of data scientists, especially those with agricultural expertise. They aim to simplify the use of AI and advanced Machine Learning in the food supply chain, so that organizations can reap the rewards of the huge advances being made, at affordable price points, using existing team members’ skills and knowledge.

Anthony Howcroft, CEO and founder of SWARM Engineering said, “I’m excited to have the capital to continue SWARM’s exciting journey in solving real-world problems for food supply chain organizations, but I’m even more thrilled to be partnering with investors who are so knowledgeable and committed to this space.”

“SWARM has developed a truly disruptive technology which harnesses AI & ML to drive massive efficiency gains across multiple verticals within the broader food supply chain. Part of what makes SWARM’s approach so revolutionary is that it democratizes AI & ML by making it both useful, and useable for its clients in the ‘real world’.” said James Ramey, Managing Member of the VTC Seed Fund.

Soren Schroeder, former CEO of Bunge a global agribusiness and food company says, “The Ag-Food supply chain is all about optimization and prediction. Often the biggest challenge is to define a problem very precisely. SWARM can help companies – large and small – define and solve very complex problems quickly, using the latest in data technology.”

The global pandemic has highlighted the critical importance of supply chains, and food has frequently made headlines – in many cases, for all the wrong reasons; who can forget seeing dramatic images of milk being poured away because of logistical challenges? “In the next few years, we have a tremendous opportunity to make a step change in efficiency and sustainability in food production and transportation,” says Howcroft, “We need to give the right tools to the people at the heart of the food supply chain to help them deliver this transformation.”

Recent News

05/22/2026

BIO Statement on Veto of Prescription Drug Affordability Boards (PDAB) in VirginiaPatrick J. Plues, Senior Vice President of State Government Affairs & Affiliate Relations at the Biotechnology Innovation Organization (BIO) released the following statement on the veto of Prescription Drug Affordability Boards (PDAB) legislation in Virginia: “BIO applauds Governor Spanberger’s decision to veto SB 271 and HB 483 — legislation that would have established a Prescription Drug Affordability Board (PDAB) and imposed arbitrary price controls in Virginia. The Governor’s action recognized an important point: even well-intentioned healthcare policies must be carefully designed to avoid unintended consequences for patients, providers, employers, and Virginia’s innovation economy. “BIO is proud to represent biotechnology companies developing the next generation of life-changing medicines, including many in the Commonwealth. We believe policymakers play a critically important role in helping advance both patient access to treatments and the continued growth of the life sciences sector. “We look forward to working with the Governor’s Administration, the General Assembly, Virginia Bio and other stakeholders to advance practical, patient-centered policy solutions that improve affordability while preserving access to care and the innovation ecosystem patients depend on.”

Patrick J. Plues, Senior Vice President of State Government Affairs & Affiliate Relations at the Biotechnology Innovation Organization (BIO) released the following statement on the veto of Prescription Drug Affordability Boards (PDAB) legislation in Virginia: “BIO applauds Governor Spanberger’s decision to veto SB 271 and HB 483 — legislation that would have established a Prescription

05/21/2026

Virginia Bio Applauds Governor Spanberger’s Veto of SB 271 and HB 483

The Virginia Biotechnology Association (Virginia Bio) today expressed strong support for Governor Abigail Spanberger’s decision to veto Senate Bill 271 and House Bill 483, legislation that would have established a Prescription Drug Affordability Advisory Panel (PDAAP) in the Commonwealth. Virginia Bio and the Virginia Chamber of Commerce sent a joint letter to Governor Spanberger commending

05/21/2026

New Global Clinical Society to Bring Focused Ultrasound Into Mainstream Medicine

The Focused Ultrasound Foundation today announced the launch of the International Focused Ultrasound Society (IFUS), a new organization dedicated to advancing clinical practice and accelerating adoption of focused ultrasound – a revolutionary, noninvasive therapeutic technology. Established as a program of the Focused Ultrasound Foundation, IFUS aggregates and expands the Foundation’s activities related to clinical implementation